MPM BioImpact — 2015 Investments
2 investments dated 2015 · listed companies and verified rows first · show all
Vascular Pharmaceuticals develops VPI-2960B, a therapeutic candidate in clinical development for diabetic nephropathy treatment.
BiotechDigital HealthMedical DevicesChapel Hill, US
Laura Maile(Co-Founder, Director, Research and Development)Richard Shea(Executive Officer, Director)inBonnie Layman(Executive Officer)David Clemmons(Co-Founder, Chief Scientific Officer)
BoardElizabeth Stoner(Director)inRichard Kent(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.